Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein
Catalog No: AFP-HP006
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and PLFQVPEPV peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &PLFQVPEPV).
Product Details
- Molecular Aliases
- Alpha-fetoprotein; Alpha-1-fetoprotein; Alpha-feto; AFP; HPAFP; AFPD; FETA; MHC
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reduced (N) condition based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per ug by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer is greater than 95% as determined by SEC-HPLC.
Background
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
References
- (1) Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clin Cancer Res. 2017 Jan 15;23(2):478-488. doi: 10.1158/1078-0432.CCR-16-1203. Epub 2016 Aug 17. PMID: 27535982.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.